Effective COVID-19 Treatment 

 

 

 

INFORMATION ONLY - NOT GUARANTEED ACCURATE

NOT MEDICAL ADVICE - CONSULT A MEDICAL PROFESSIONAL

"The widespread use of this safe, inexpensive, and effective intervention [with Ivermectin] could lead to a drastic reduction in transmission rates as well as the morbidity and mortality in mild, moderate, and even severe disease phases."

FLCCC Alliance (https://covid19criticalcare.com)

"The government could end the pandemic by openly encouraging doctors to prescribe these approved medications" (ivermectin, zinc, doxycycline) Thomas Borody MD, PhD - worked with Nobel Prize winners for cure of peptic ulcers. 

“Historians will say it was a colossal strategic blunder that government did not invest in these early treatments (including clinical trials) to prevent hospitalizations and deaths. It is time for the FDA and state medical boards to support the use of Ivermectin and Hydroxychloroquine in conjunction with other commonly used drugs”. Peter A. McCullough, MD, Vice Chairman of Medicine, Baylor University Medical Center  

"When Hydroxychloroquine is given very early in the course of illness, before the virus has had time to multiply beyond control, it has shown to be highly effective, when given in combination with antibiotics and zinc."  Harvey A. Risch, MD, PhD, Professor of Epidemiology, Yale School of Public Health  

Ivermectin (IVM) is effective over most phases of the COVID-19 disease (prevention, mild, severe) based on its anti-viral and anti-inflammatory characteristics. HCQ+Zinc possibly is effective if it is used early, at first symptoms (note: publicized failed clinical trials of HCQ for COVID-19 included severe late-stage hospitalized patients, not early stage outpatients, and did not include the necessary Zinc).

Based on successful case experience and clinical studies, combinations of the following have been effective for early - and often later stage - therapy for COVID-19:

   Viral inhibitors

   Antibiotics

   Anticoagulants

   Anti-inflammatories 

   Supplements

Each drug and supplement affects the viral mechanisms or the immune system response.

Ivermectin Mechanisms with COVID-19

   1. Inhibits binding at spike

   2. Blocks alpha-importin subunit so the virus loses transport into the cell

   3. Protease inhibitor effect inhibits viral unloading

   4. Inhibits RNA dependent replicase replication site

   5. Stimulates up regulation of natural interferon by the nucleus which signals surrounding cells to resist infection 

   6. Down regulates inflammatory cytokines

   7. Binds to cd147 on platelets and red cells and/or regulates antibodies inhibiting excessive clotting

   8. NF kappa beta modulation for a quicker T cell response

These mechanisms make Ivermectin effective both against the virus and in modulating the immune system.

IVM is an antiviral that blocks the coronavirus from entering a cell ... and appears to be have immunomodulation properties as well that help control immune dysregulation. Research indicates that IVM also may be an ionophore that helps enable Zinc to limit the coronavirus, further enhancing the benefits of IVM.  Having both antiviral and immunomodulating properties makes IVM a very effective therapy component across the viral and the inflammatory phases of the disease. IVM also appears to inhibit blood clotting, one of the most serious problems with COVID-19.

HCQ is an "ionophore" which helps transport zinc across the cytoplasmic membrane of infected cells and increases the amount of Zinc within the cells so that the Zinc better can eliminate the virus. HCQ plus Zinc are essential for effective treatment. The ionophore is the "gun" and Zinc is the "bullet' ... both are needed.  A number of HCQ clinical trials have not included Zinc rendering the trial results not useful.

In addition to its antiviral properties, Zinc also is an essential component of Superoxide Dismutase (a key enzyme). Viral infections deplete large amounts of Superoxide Dismutase, and supplementation with Zinc is needed.

Sufficient levels of Vitamin D produce anti‐microbial proteins (in the innate immune system) that destroy the SARS-CoV-2 coronavirus as well as enhance the adaptive immune system to help regulate inflammation. Since viral replication increases several days before symptoms start, sufficient Vitamin D levels at all times are important to help prevent and to limit COVID-19. 

In addition, prophylactic (preventative) use of these these medications and supplements help mitigate viral replication and resulting symptoms.

Studies indicate that intestinal bacteria may be altered by COVID-19, which could affect how sick a patient becomes with the disease and potentially how long it lasts. The imbalance of the intestinal bacteria, even after the disease itself was resolved, could be a contributing factor to what is called “long haul" COVID-19, symptoms that persist for months.

An estimated 10% to 45% of people who become ill with COVID-19 will have symptoms after the acute stage of the disease (aka

"Long Haulers"). Ongoing research seeks to determine if long covid pathology is highly unique to COVID-19 or, instead, is a manifestation of the longer-term diverse symptoms in some patients of other illnesses (such as traditional flu) that have been well-known for years.  These long symptoms can persist for a few weeks to years after the initial symptoms of an illness.

 

A preprint study (https://www.researchgate.net/publication/344318845_POST-ACUTE_OR_PROLONGED_COVID-19_IVERMECTIN_TREATMENT_FOR_PATIENTS_WITH_PERSISTENT_SYMPTOMS_OR_POST-ACUTE)  concludes that clinical improvement is observed in a high percentage of "Long Hauler"patients who are treated with Ivermectin.

Resources for long haulers can be found at:

     https://covidlonghaulers.com

     https://www.facebook.com/groups/416179869477953

     https://covid19criticalcare.com/wp-content/uploads/2020/12/FLCCC-Protocols-–-A-Guide-to-the-Management-of-COVID-19.pdf

--------------------------------------------------------------------------------------------------------------- 

In the USA ...

National Institutes of Health (NIH) Recommendation.  Last Updated: January 14, 2021

The COVID-19 Treatment Guidelines Panel has determined that currently there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin for the treatment of COVID-19.

(Note: The NIH recommendation now has upgraded Ivermectin to the same level as NIH recommendations for the monoclonal antibodiey combinations of Regeneron and Eli Lilly).  https://www.covid19treatmentguidelines.nih.gov/statement-on-ivermectin/ 

Some medical professionals will prescribe the Regeneron or the Eli Lilly monoclonal antibody combination therapies which received FDA Emergency Use Authorization (EUA) plus Ivermectin to maximize the antiviral activity in early diseases outpatients. The Regeneron and Eli Lilly drugs must be administered intravenously in a medical facility.https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab 

--------------------------------------------------------------------------------------------------------------- 

Typical COVID-19 Disease Progression  

DAY 0 

  • The virus is introduced to your body mostly through airborne particles

  • No symptoms ... but you may be contagious

  • Viral replication begins in the nose and mouth

  • The virus progresses into the lungs 

DAY 5 

  • First symptoms appear

  • The virus then makes its way into other organs of the body 

  • Innate and adaptive immune reactions increase 

  • Viral replication begins to decline and viral debris increases  

  • Blood clotting may begin

DAY 10

  • If not regulated inherently and/or with treatment, immune system dysregulation increases 

 

------------------------------------------------------------------------------------------------------------------ 

------------------------------------------------------------------------------------------------------------------ 

------------------------------------------------------------------------------------------------------------------------------------------------------------- 

COVID-19 Treatment Protocols

COVID-19 Protocols: Prophylaxis, Treatment, Long Haul 
      https://c19protocols.com

------------------------------------------------------------------------------------------------------------------------------------------------------------- 

FLCCC 4.26.2021 pg 2.jpg

--------------------------------------------------------------------------------------------------------

Peter A. McCullough, Vice Chairman Medicine Baylor University Medical Center; et al

Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection 

https://www.amjmed.com/article/S0002-9343(20)30673-2/fulltext

--------------------------------------------------------------------------------------------------------

--------------------------------------------------------------------------------------------------------

-------------------------------------------------------------------------------------------------------- 

Dr. Vladimir Zelenko         https://www.vladimirzelenkomd.com

Zelenko Treatment.jpg

-------------------------------------------------------------------------------------------------------- 

Blaine White, M.D.

   On Covid-19 for WSU Emergency Medicine Residents. 6th Edition (updated March 10, 2021)

-------------------------------------------------------------------------------------------------------- 

-------------------------------------------------------------------------------------------------------- 

Dr. Alexis Lieberman

-------------------------------------------------------------------------------------------------------- 

Matrix 4.16.2021.jpg

Based on original chart by Dr. Mobeen Syed

-------------------------------------------------------------------------------------------------------- 

Listing of early home-based treatment kits provided for acute COVID-19 illness by various countries

LIMITATION OF LIABILITY

This information is provided as a not-for-profit public service by people who are not medical professionals.

In no event shall we or our affiliates be liable for any special, incidental or consequential damages arising out of or in connection with this information or website, including negligence.  

BY USING THIS WEBSITE OR INFORMATION, YOU AGREE TO THESE TERMS.